Clinical evidence of the effects of carnitine supplementation on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: a systematic review and meta-analysis

References

• McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54–64.
   PubMed Web of Science ®Google Scholar
• Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2020;26(6):942–960.
   PubMed Web of Science ®Google Scholar
• Cooney LG, Dokras A. Cardiometabolic risk in polycystic ovary syndrome: current guidelines. Endocrinol Metab Clin North Am. 2021;50(1):83–95.
   PubMed Web of Science ®Google Scholar
• Bruni V, Capozzi A, Lello S. The role of genetics, epigenetics and lifestyle in polycystic ovary syndrome development: the state of the art. Reprod Sci. 2021.doi: https://doi.org/10.1007/s43032-021-00515-4.
   Web of Science ®Google Scholar
• Goodarzi MO, Dumesic DA, Chazenbalk G, et al. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231.
   PubMed Web of Science ®Google Scholar
• Arentz S, Smith CA, Abbott J, et al. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17(1):500.
   PubMedGoogle Scholar
• Liao D, Zhong C, Li C, et al. Meta-analysis of the effects of probiotic supplementation on glycemia, lipidic profiles, weight loss and C-reactive protein in women with polycystic ovarian syndrome. Minerva Med. 2018;109(6):479–487.
   PubMedGoogle Scholar
• Faghfoori Z, Fazelian S, Shadnoush M, et al. Nutritional management in women with polycystic ovary syndrome: a review study. Diabetes Metab Syndr. 2017;11(Suppl 1):S429–S432.
   PubMedGoogle Scholar
• Chakraborty P, Ghosh S, Goswami SK, et al. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res. 2013;152(1):9–15.
   PubMedGoogle Scholar
• Heydarpour F, Hemati N, Hadi A, et al. Effects of cinnamon on controlling metabolic parameters of polycystic ovary syndrome: a systematic review and meta-analysis. J Ethnopharmacol. 2020;254:112741.
   PubMedGoogle Scholar
• El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015;116(3):107–112.
   PubMedGoogle Scholar
• Borum PR. Carnitine. Annu Rev Nutr. 1983;3:233–259.
   PubMed Web of Science ®Google Scholar
• Power RA, Hulver MW, Zhang JY, et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia. 2007;50(4):824–832.
   PubMedGoogle Scholar
• Xu Y, Jiang W, Chen G, et al. L-carnitine treatment of insulin resistance: a systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333–338.
   PubMed Web of Science ®Google Scholar
• Vigerust NF, Bohov P, Bjørndal B, et al. Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertil Steril. 2012;98(6):1620–1626 e1621.
   PubMed Web of Science ®Google Scholar
• Samimi M, Jamilian M, Ebrahimi FA, et al. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol. 2016;84(6):851–857.
   PubMed Web of Science ®Google Scholar
• Jamilian H, Jamilian M, Samimi M, et al. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol. 2017;33(6):442–447.
   PubMed Web of Science ®Google Scholar
• Pakravanfar F, Ghadiri-Anari A, Nadjarzadeh A, et al. The effect of l-carnitine supplementation on weight and body composition in women with polycystic ovary syndrome: a double-blind randomized clinical trial. JNFS. 2020;5(3):282–289.
   Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
   PubMed Web of Science ®Google Scholar
• El Sharkwy IA, Abd El Aziz WM. Randomized controlled trial of N-acetylcysteine versus l-carnitine among women with clomiphene-citrate-resistant polycystic ovary syndrome. Int J Gynecol Obstet. 2019;147(1):59–64.
   PubMedGoogle Scholar
• El Sharkwy I, Sharaf El-Din M. l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. Gynecol Endocrinol. 2019;35(8):701–705.
   PubMed Web of Science ®Google Scholar
• Talari HR, Azad ZJ, Hamidian Y, et al. Effects of carnitine administration on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Int J Prev Med. 2019;10(1):89.
   PubMedGoogle Scholar
• Fenkci SM, Fenkci V, Oztekin O, et al. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod. 2008;23(7):1602–1606.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xie YJ, Qu LH, et al. Dyslipidemia involvement in the development of polycystic ovary syndrome. Taiwan J Obstet Gynecol. 2019;58(4):447–453.
   PubMedGoogle Scholar
• Zhang Y, Liu L, Yin TL, et al. Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients. Oncotarget. 2017;8(46):80472–80480.
   PubMedGoogle Scholar
• Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422–2435.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Liu YY, Liu GH, et al. l-Carnitine and heart disease. Life Sci. 2018;194:88–97.
   PubMed Web of Science ®Google Scholar
• DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013;88(6):544–551.
   PubMed Web of Science ®Google Scholar
• Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–784.
   PubMed Web of Science ®Google Scholar
• Celik F, Kose M, Yilmazer M, et al. Plasma L-carnitine levels of obese and non-obese polycystic ovary syndrome patients. J Obstet Gynaecol. 2017;37(4):476–479.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030.
   PubMed Web of Science ®Google Scholar
• Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007;581(Pt 2):431–444.
   PubMed Web of Science ®Google Scholar
• Zammit VA, Ramsay RR, Bonomini M, et al. Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev. 2009;61(14):1353–1362.
   PubMedGoogle Scholar
• Barber TM, Hanson P, Weickert MO, et al. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019;13:1179558119874042.
   Web of Science ®Google Scholar
• Baldani DP, Skrgatic L, Ougouag R, et al. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment. Gynecol Endocrinol. 2018;34(2):87–91.
   PubMed Web of Science ®Google Scholar